Living Cell Technologies Limited has completed treatment of all six patients in the third and final group of patients in the Phase IIb clinical trial of NTCELL for Parkinson’s disease, at Auckland City Hospital (New Zealand).
http://www.lctglobal.com/upload/news...0completed.pdf
(hat tip to catlou at HU for the heads-up)